サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1069285

ペプチド治療薬の世界市場予測（2021年～2028年）

Peptide Therapeutics - Global Market Outlook (2021 - 2028)
出版日: | 発行: Stratistics Market Research Consulting | ページ情報: 英文 200+ Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
ペプチド治療薬の世界市場予測（2021年～2028年）
出版日: 2022年04月01日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のペプチド治療薬の市場規模は、2021年に319億3,000万米ドルとなり、2028年までには565億2,000万米ドルに達し、予測期間中に8.5％のCAGRで成長すると予測されています。

当レポートでは、世界のペプチド治療薬市場について調査分析し、市場動向、競合情勢、セグメント別・地域別の市場分析、主要企業のプロファイルなど、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 序文

第3章 市場動向分析

  • イントロダクション
  • 促進要因
  • 抑制要因
  • 市場機会
  • 脅威
  • 技術分析
  • 用途分析
  • エンドユーザー分析
  • 新興市場
  • COVID-19の影響

第4章 ポーターのファイブフォース分析

第5章 世界のペプチド治療薬市場：合成技術別

  • イントロダクション
  • 固相ペプチド合成（SPPS）
  • 液相ペプチド合成（LPPS）
  • ハイブリッド技術

第6章 世界のペプチド治療薬市場：投与経路別

  • イントロダクション
  • 肺
  • 非経口
  • 経口
  • 粘膜
  • 注射
  • その他の投与経路
    • 皮内
    • 鼻

第7章 世界のペプチド治療薬市場：タイプ別

  • イントロダクション
  • 新薬
  • ジェネリック
  • ブランド

第8章 世界のペプチド治療薬市場：メーカータイプ別

  • イントロダクション
  • 外注
  • 社内
  • 受託製造機関（CMO）

第9章 世界のペプチド治療薬市場：分子タイプ別

  • イントロダクション
  • バソプレッシン
  • ソマトスタチン
  • ナトリウム利尿剤
  • 黄体形成ホルモン（LH） - 放出ホルモン（LHRH）
  • インスリン
  • 免疫ペプチド
  • グルカゴン・類似体
  • カルシトニン

第10章 世界のペプチド治療薬市場：用途別

  • イントロダクション
  • 先端巨大症
  • 抗感染症
  • 癌
    • ルプロン・エナントン・エリガード（リュープロレリン）
    • ベルケイド（ボルテゾミブ）
    • ゾラデックス（ゴセレリン）
  • 心血管障害
    • アンジオマックス（ビバリルジン）
    • インテグリリン（エプチフィバチド）
  • 中枢神経系（コパキソン（グラチラマー））
  • 皮膚
  • 胃腸感染症（GIT）
    • ガテックス（テデュグルチド）
    • リンゼス（リナクロチド）
  • 血液疾患
    • フィラジル（イカティバント）
    • カルビトール（エカランタイド）
  • 感染
    • インシベック（テラプレビル）
    • ビクトレリス（ボセプレビル）
  • 代謝
    • ヴィクトーザ（リラグルチド）
    • ビエッタ（エクセナチド）
  • 疼痛
  • 腎臓
  • 呼吸器
  • その他の用途
    • 骨粗鬆症
    • アレルギー・免疫

第11章 世界のペプチド治療薬市場：エンドユーザー別

  • イントロダクション
  • 製薬・バイオテクノロジー産業
  • 病院
  • 受託研究機関
  • 学術研究

第12章 世界のペプチド治療薬市場：地域別

  • イントロダクション
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他アジア太平洋
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他南米
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他中東・アフリカ

第13章 主な発展

  • 契約、パートナーシップ、提携、共同事業
  • 買収・合併
  • 新製品の発売
  • 事業拡張
  • その他の重要戦略

第14章 企業プロファイル

  • Amgen Inc
  • AstraZeneca PLC
  • Bachem Holding AG
  • Bristol-Myers Squibb(BMS)
  • Eli Lilly and Company
  • GlaxoSmithKline(GSK)
  • ISSAR Pharmaceuticals
  • Lonza Inc
  • Merck & Co
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Xenetic Biosciences, Inc
図表

List of Tables

  • Table 1 Global Peptide Therapeutics Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Peptide Therapeutics Market Outlook, By Synthesis Technology (2020-2028) ($MN)
  • Table 3 Global Peptide Therapeutics Market Outlook, By Solid Phase Peptide Synthesis (SPPS) (2020-2028) ($MN)
  • Table 4 Global Peptide Therapeutics Market Outlook, By Liquid Phase Peptide Synthesis (LPPS) (2020-2028) ($MN)
  • Table 5 Global Peptide Therapeutics Market Outlook, By Hybrid Technology (2020-2028) ($MN)
  • Table 6 Global Peptide Therapeutics Market Outlook, By Route of Administration (2020-2028) ($MN)
  • Table 7 Global Peptide Therapeutics Market Outlook, By Pulmonary (2020-2028) ($MN)
  • Table 8 Global Peptide Therapeutics Market Outlook, By Parenteral (2020-2028) ($MN)
  • Table 9 Global Peptide Therapeutics Market Outlook, By Oral (2020-2028) ($MN)
  • Table 10 Global Peptide Therapeutics Market Outlook, By Mucosal (2020-2028) ($MN)
  • Table 11 Global Peptide Therapeutics Market Outlook, By Injection (2020-2028) ($MN)
  • Table 12 Global Peptide Therapeutics Market Outlook, By Other Route of Administrations (2020-2028) ($MN)
  • Table 13 Global Peptide Therapeutics Market Outlook, By Intradermal (2020-2028) ($MN)
  • Table 14 Global Peptide Therapeutics Market Outlook, By Nasal (2020-2028) ($MN)
  • Table 15 Global Peptide Therapeutics Market Outlook, By Type (2020-2028) ($MN)
  • Table 16 Global Peptide Therapeutics Market Outlook, By Innovative (2020-2028) ($MN)
  • Table 17 Global Peptide Therapeutics Market Outlook, By Generic (2020-2028) ($MN)
  • Table 18 Global Peptide Therapeutics Market Outlook, By Branded (2020-2028) ($MN)
  • Table 19 Global Peptide Therapeutics Market Outlook, By Type of Manufacturer (2020-2028) ($MN)
  • Table 20 Global Peptide Therapeutics Market Outlook, By Outsourced (2020-2028) ($MN)
  • Table 21 Global Peptide Therapeutics Market Outlook, By In-house (2020-2028) ($MN)
  • Table 22 Global Peptide Therapeutics Market Outlook, By Contract Manufacturing Organizations (CMOs) (2020-2028) ($MN)
  • Table 23 Global Peptide Therapeutics Market Outlook, By Type of Molecule (2020-2028) ($MN)
  • Table 24 Global Peptide Therapeutics Market Outlook, By Vasopressin (2020-2028) ($MN)
  • Table 25 Global Peptide Therapeutics Market Outlook, By Somatostatin (2020-2028) ($MN)
  • Table 26 Global Peptide Therapeutics Market Outlook, By Natriuretic (2020-2028) ($MN)
  • Table 27 Global Peptide Therapeutics Market Outlook, By Luteinizing Hormone (LH)-Releasing Hormone (LHRH) (2020-2028) ($MN)
  • Table 28 Global Peptide Therapeutics Market Outlook, By Insulins (2020-2028) ($MN)
  • Table 29 Global Peptide Therapeutics Market Outlook, By Immunopeptide (2020-2028) ($MN)
  • Table 30 Global Peptide Therapeutics Market Outlook, By Glucagon and Analogs (2020-2028) ($MN)
  • Table 31 Global Peptide Therapeutics Market Outlook, By Calcitonin (2020-2028) ($MN)
  • Table 32 Global Peptide Therapeutics Market Outlook, By Application (2020-2028) ($MN)
  • Table 33 Global Peptide Therapeutics Market Outlook, By Acromegaly (2020-2028) ($MN)
  • Table 34 Global Peptide Therapeutics Market Outlook, By Anti-infection (2020-2028) ($MN)
  • Table 35 Global Peptide Therapeutics Market Outlook, By Cancer (2020-2028) ($MN)
  • Table 36 Global Peptide Therapeutics Market Outlook, By Lupron/ Enantone/ Eligard (Leuprorelin) (2020-2028) ($MN)
  • Table 37 Global Peptide Therapeutics Market Outlook, By Velcade (Bortezomib) (2020-2028) ($MN)
  • Table 38 Global Peptide Therapeutics Market Outlook, By Zoladex (Goserelin) (2020-2028) ($MN)
  • Table 39 Global Peptide Therapeutics Market Outlook, By Cardiovascular Disorder (2020-2028) ($MN)
  • Table 40 Global Peptide Therapeutics Market Outlook, By Angiomax (Bivalirudin) (2020-2028) ($MN)
  • Table 41 Global Peptide Therapeutics Market Outlook, By Integrilin (Eptifibatide) (2020-2028) ($MN)
  • Table 42 Global Peptide Therapeutics Market Outlook, By Central Nervous System (Copaxone (Glatiramer)) (2020-2028) ($MN)
  • Table 43 Global Peptide Therapeutics Market Outlook, By Dermatology (2020-2028) ($MN)
  • Table 44 Global Peptide Therapeutics Market Outlook, By Gastro-Intestinal Infection (GIT) (2020-2028) ($MN)
  • Table 45 Global Peptide Therapeutics Market Outlook, By Gattex (Teduglutide) (2020-2028) ($MN)
  • Table 46 Global Peptide Therapeutics Market Outlook, By Linzess (Linaclotide) (2020-2028) ($MN)
  • Table 47 Global Peptide Therapeutics Market Outlook, By Hematological Disorders (2020-2028) ($MN)
  • Table 48 Global Peptide Therapeutics Market Outlook, By Firazyr (Icatibant) (2020-2028) ($MN)
  • Table 49 Global Peptide Therapeutics Market Outlook, By Kalbitor (Ecallantide) (2020-2028) ($MN)
  • Table 50 Global Peptide Therapeutics Market Outlook, By Infection (2020-2028) ($MN)
  • Table 51 Global Peptide Therapeutics Market Outlook, By Incivek (Telaprevir) (2020-2028) ($MN)
  • Table 52 Global Peptide Therapeutics Market Outlook, By Victrelis (Boceprevir) (2020-2028) ($MN)
  • Table 53 Global Peptide Therapeutics Market Outlook, By Metabolic (2020-2028) ($MN)
  • Table 54 Global Peptide Therapeutics Market Outlook, By Victoza (Liraglutide) (2020-2028) ($MN)
  • Table 55 Global Peptide Therapeutics Market Outlook, By Byetta (Exenatide) (2020-2028) ($MN)
  • Table 56 Global Peptide Therapeutics Market Outlook, By Pain (2020-2028) ($MN)
  • Table 57 Global Peptide Therapeutics Market Outlook, By Renal (2020-2028) ($MN)
  • Table 58 Global Peptide Therapeutics Market Outlook, By Respiratory (2020-2028) ($MN)
  • Table 59 Global Peptide Therapeutics Market Outlook, By Other Applications (2020-2028) ($MN)
  • Table 60 Global Peptide Therapeutics Market Outlook, By Osteoporosis (2020-2028) ($MN)
  • Table 61 Global Peptide Therapeutics Market Outlook, By Allergy/Immunological (2020-2028) ($MN)
  • Table 62 Global Peptide Therapeutics Market Outlook, By End User (2020-2028) ($MN)
  • Table 63 Global Peptide Therapeutics Market Outlook, By Pharmaceutical and Biotechnology Industries (2020-2028) ($MN)
  • Table 64 Global Peptide Therapeutics Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 65 Global Peptide Therapeutics Market Outlook, By Contract Research Organization (2020-2028) ($MN)
  • Table 66 Global Peptide Therapeutics Market Outlook, By Academic and Research Institutes (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

目次
Product Code: SMRC19307

According to Stratistics MRC, the Global Peptide Therapeutics Market is accounted for $31.93 billion in 2021 and is expected to reach $56.52 billion by 2028 growing at a CAGR of 8.5% during the forecast period. Peptides are the combination of two or more amino acid monomers linked by amide bonds. Researchers have demonstrated that peptide is distinguished from proteins on the basis of size. As a benchmark, molecules with less than 50 amino acids are considered as peptides. Peptides act by binding to specific cell surface receptors and mimics like receptor ligands and help in treatment of diseases by acting on the cell membrane. Peptides initially had applications only in diagnostics and hormonal therapy; however, with advances in technology, peptides are now being widely applied for therapeutic applications of cancer and chronic metabolic diseases.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

The major factor driving the market growth is the increasing prevalence of cancer and metabolic disorders along with the technological advancements in peptide therapeutics. According to the World Health Organization (WHO), chronic diseases, such as cancer, cardiovascular diseases, and diabetes, are the leading causes of death and disability worldwide. Disease rates from chronic conditions are accelerating globally, advancing across every region and pervading all socioeconomic classes. In 2020, the contribution of chronic diseases was estimated to have caused 73% of all deaths and 60% of the global burden of diseases. Thus, the increasing incidence of chronic diseases accelerates the need for effective therapeutics, which in turn, is expected to drive the growth of the peptide therapeutics market.

Restraint:

Instability of peptides

One of the true drawbacks of peptide drugs is the increased proteolytic instability compared to not only small molecules but also monoclonal antibody therapeutics. The Fc fragment of monoclonal antibodies reshuffle the protein to cells and peptide-Fc conjugates may also be protected from enzymatic cleavage. Chemically, both the amide bond and the side-chains can be altered to render the resulting peptidomimetics resistant to proteolytic degradation. The serum stability assay provides a ready measure of peptide stability and was once considered the most significant secondary screening tool in drug development. Indeed, serum stability can provide a strong prediction of the all-important pharmacokinetic behavior of drugs. Chemical instability involves damage of the primary structure, covalent modification of the protein through bond formation or cleavage.

Opportunity:

Growing adoption of synthetic peptide drugs

Synthetic peptide drugs can be made to look like naturally occurring peptides and can be used to treat cancer and other serious illnesses. Synthetic peptides are chemically synthesized small polymers of amino acids. Synthetic peptides are used as affinity ligands. Several companies are capable of synthesizing peptides of up to 100 amino acid residues as a custom peptide synthesis service. Peptides are nowadays readily available by synthetic methodologies and can be produced in large quantities at low cost. They are obtained as defined and pure chemical entities, eliminating variability in biological results, and their use is devoid of infection and immunogenic risks. For instance, Hemmo has been supplying peptide products and custom peptide synthesis for more than 38 years, making it one of India's major makers of synthetic peptide drugs provider.

Threat:

Stringent regulatory challenges

The increasing interest of the pharmaceutical industry in peptide therapeutics has been a catalyst for the development of regulations in this area. Nevertheless, manufacturers and regulators continue to encounter scientific and regulatory challenges when dealing with peptides as active pharmaceutical ingredients in drug products. Being at the borderline between typical small molecules and large proteins, peptides have raised a series of regulatory challenges. Since there are various peptide conjugate candidates that contain peptides in combination with small molecules, the regulatory aspect for peptide is still evolving. The FDA takes into account the history and manufacturing aspect of the candidate molecule to decide its regulatory pathway Example whether BLA would be submitted or NDA needs to be applied. Disparities in interpretation and application of existing International Council for Harmonisation (ICH) and United States Food and Drug Administration (FDA) regulatory guidances have resulted in challenges, inconsistencies, and confusion for both regulators and drug developers.

The cancer segment is expected to be the largest during the forecast period

The cancer segment is estimated to have a lucrative growth. Peptides offer favorable prospects in targeted drug delivery for cancer due to their high specificity, discernment, small sizes, ease of modification, and high biocompatibility. The increasing frequency of cancer globally and increasing prescription of peptide therapeutics for cancer treatment are the key factors responsible for the dominance of this segment. Moreover, the high prevalence of cancer cases globally is expected to play a vital role in the growth of the studied segment over the forecast period. Furthermore, rising awareness among patients and healthcare professionals regarding the adverse effects of chemotherapy and radiation therapy is a major factor for the growing focus on alternative therapeutics such as peptide-based drugs.

The oral segment is expected to have the highest CAGR during the forecast period

The oral segment is anticipated to witness the fastest CAGR growth during the forecast period. Due to a decrease in non-peptide chemical medications accessible in the market, sales of peptide therapeutic companies are currently rising. As peptides are a common component of food, both, the stomach and intestines contain a plethora of enzymes that can break them down, and most peptide-based drugs do not survive the gastrointestinal tract. The peptides generics market is expected to develop as the patent cliff rises. Because pharma businesses are shifting their focus to better potential in the peptide therapies sector, CMOs that provide end-to-end services to biotech pharmaceutical companies are rising. For instance, Heinis's Group is currently using a novel technology to develop oral peptide drugs that act directly on gastrointestinal targets, bypassing the bloodstream. Oral peptide drugs will play a crucial role in the treatment of a wide range of disorders.

Region with highest share:

North America is projected to hold the largest market share during the forecast period. North America is expected to dominate the overall market throughout the forecast period. The market growth is due to factors such as a rise in awareness levels relating to peptide therapeutic products, the increasing necessity for diagnostics in cancer and other diseases, and the growing biotechnology industry. A properly established biopharmaceutical and pharmaceutical industry in this region is a major factor responsible for growth. In the North American region, the United States holds the largest market share due to factors such as the increasing number of research programs in the medical industry and the growing number of diseases in the country, which is anticipated to stimulate the demand in this region. Owing to the increasing burden of cancer, the demand for peptide therapeutics is expected to grow. Hence, given the aforementioned factors, the peptide therapeutics market is expected to witness significant growth in North America over the forecast period.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period. Vast patient pool, increasing healthcare expenditure and demand for newer advanced therapies are key factors likely to boost peptide therapeutics market in Asia Pacific. Government funding for the use of peptides in the production of COVID-19 vaccines is expected to provide a potential incentive for the adoption of the peptides, potentially driving the growth of the APAC peptide therapeutics market.

Key players in the market

Some of the key players profiled in the Peptide Therapeutics Market include Bachem Holding AG, Bristol-Myers Squibb(BMS), Eli Lilly and Company, GlaxoSmithKline (GSK), ISSAR Pharmaceuticals, Lonza Inc, Merck & Co, Novartis AG, Novo Nordisk A/S, Pfizer Inc, Sanofi, Takeda Pharmaceutical Company Limited, and Xenetic Biosciences, Inc.

Key Developments:

In May 2021, ISSAR Pharmaceuticals took the decision to license out its peptide-based new chemical entities (NCEs) with pre-IND filing and the United States Patent for various unmet healthcare needs of the population, making it affordable and accessible for better health outcomes.

In July 2019, Xenetic Biosciences, Inc. completed acquisition of the novel CAR T ("Chimeric Antigen Receptor T Cell") platform technology, called "XCART," designed to use screening technique to identify peptide ligands that bind specifically to the unique B-cell receptor of malignant tumor cells.

Synthesis Technologies Covered:

  • Solid Phase Peptide Synthesis (SPPS)
  • Liquid Phase Peptide Synthesis (LPPS)
  • Hybrid Technology

Route of Administrations Covered:

  • Pulmonary
  • Parenteral
  • Oral
  • Mucosal
  • Injection
  • Other Route of Administrations

Types Covered:

  • Innovative
  • Generic
  • Branded

Type of Manufacturers Covered:

  • Outsourced
  • In-house
  • Contract Manufacturing Organizations (CMOs)

Type of Molecules Covered:

  • Vasopressin
  • Somatostatin
  • Natriuretic
  • Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
  • Insulins
  • Immunopeptide
  • Glucagon and Analogs
  • Calcitonin

Applications Covered:

  • Acromegaly
  • Anti-infection
  • Cancer
  • Cardiovascular Disorder
  • Central Nervous System (Copaxone (Glatiramer))
  • Dermatology
  • Gastro-Intestinal Infection (GIT)
  • Hematological Disorders
  • Infection
  • Metabolic
  • Pain
  • Renal
  • Respiratory
  • Other Applications

End Users Covered:

  • Pharmaceutical and Biotechnology Industries
  • Hospitals
  • Contract Research Organization
  • Academic and Research Institutes

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Peptide Therapeutics Market, By Synthesis Technology

  • 5.1 Introduction
  • 5.2 Solid Phase Peptide Synthesis (SPPS)
  • 5.3 Liquid Phase Peptide Synthesis (LPPS)
  • 5.4 Hybrid Technology

6 Global Peptide Therapeutics Market, By Route of Administration

  • 6.1 Introduction
  • 6.2 Pulmonary
  • 6.3 Parenteral
  • 6.4 Oral
  • 6.5 Mucosal
  • 6.6 Injection
  • 6.7 Other Route of Administrations
    • 6.7.1 Intradermal
    • 6.7.2 Nasal

7 Global Peptide Therapeutics Market, By Type

  • 7.1 Introduction
  • 7.2 Innovative
  • 7.3 Generic
  • 7.4 Branded

8 Global Peptide Therapeutics Market, By Type of Manufacturer

  • 8.1 Introduction
  • 8.2 Outsourced
  • 8.3 In-house
  • 8.4 Contract Manufacturing Organizations (CMOs)

9 Global Peptide Therapeutics Market, By Type of Molecule

  • 9.1 Introduction
  • 9.2 Vasopressin
  • 9.3 Somatostatin
  • 9.4 Natriuretic
  • 9.5 Luteinizing Hormone (LH)-Releasing Hormone (LHRH)
  • 9.6 Insulins
  • 9.7 Immunopeptide
  • 9.8 Glucagon and Analogs
  • 9.9 Calcitonin

10 Global Peptide Therapeutics Market, By Application

  • 10.1 Introduction
  • 10.2 Acromegaly
  • 10.3 Anti-infection
  • 10.4 Cancer
    • 10.4.1 Lupron/ Enantone/ Eligard (Leuprorelin)
    • 10.4.2 Velcade (Bortezomib)
    • 10.4.3 Zoladex (Goserelin)
  • 10.5 Cardiovascular Disorder
    • 10.5.1 Angiomax (Bivalirudin)
    • 10.5.2 Integrilin (Eptifibatide)
  • 10.6 Central Nervous System (Copaxone (Glatiramer))
  • 10.7 Dermatology
  • 10.8 Gastro-Intestinal Infection (GIT)
    • 10.8.1 Gattex (Teduglutide)
    • 10.8.2 Linzess (Linaclotide)
  • 10.9 Hematological Disorders
    • 10.9.1 Firazyr (Icatibant)
    • 10.9.2 Kalbitor (Ecallantide)
  • 10.10 Infection
    • 10.10.1 Incivek (Telaprevir)
    • 10.10.2 Victrelis (Boceprevir)
  • 10.11 Metabolic
    • 10.11.1 Victoza (Liraglutide)
    • 10.11.2 Byetta (Exenatide)
  • 10.12 Pain
  • 10.13 Renal
  • 10.14 Respiratory
  • 10.15 Other Applications
    • 10.15.1 Osteoporosis
    • 10.15.2 Allergy/Immunological

11 Global Peptide Therapeutics Market, By End User

  • 11.1 Introduction
  • 11.2 Pharmaceutical and Biotechnology Industries
  • 11.3 Hospitals
  • 11.4 Contract Research Organization
  • 11.5 Academic and Research Institutes

12 Global Peptide Therapeutics Market, By Geography

  • 12.1 Introduction
  • 12.2 North America
    • 12.2.1 US
    • 12.2.2 Canada
    • 12.2.3 Mexico
  • 12.3 Europe
    • 12.3.1 Germany
    • 12.3.2 UK
    • 12.3.3 Italy
    • 12.3.4 France
    • 12.3.5 Spain
    • 12.3.6 Rest of Europe
  • 12.4 Asia Pacific
    • 12.4.1 Japan
    • 12.4.2 China
    • 12.4.3 India
    • 12.4.4 Australia
    • 12.4.5 New Zealand
    • 12.4.6 South Korea
    • 12.4.7 Rest of Asia Pacific
  • 12.5 South America
    • 12.5.1 Argentina
    • 12.5.2 Brazil
    • 12.5.3 Chile
    • 12.5.4 Rest of South America
  • 12.6 Middle East & Africa
    • 12.6.1 Saudi Arabia
    • 12.6.2 UAE
    • 12.6.3 Qatar
    • 12.6.4 South Africa
    • 12.6.5 Rest of Middle East & Africa

13 Key Developments

  • 13.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 13.2 Acquisitions & Mergers
  • 13.3 New Product Launch
  • 13.4 Expansions
  • 13.5 Other Key Strategies

14 Company Profiling

  • 14.1 Amgen Inc
  • 14.2 AstraZeneca PLC
  • 14.3 Bachem Holding AG
  • 14.4 Bristol-Myers Squibb(BMS)
  • 14.5 Eli Lilly and Company
  • 14.6 GlaxoSmithKline (GSK)
  • 14.7 ISSAR Pharmaceuticals
  • 14.8 Lonza Inc
  • 14.9 Merck & Co
  • 14.10 Novartis AG
  • 14.11 Novo Nordisk A/S
  • 14.12 Pfizer Inc
  • 14.13 Sanofi
  • 14.14 Takeda Pharmaceutical Company Limited
  • 14.15 Xenetic Biosciences, Inc